Journal
BMJ GLOBAL HEALTH
Volume 6, Issue SUPPL_3, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bmjgh-2020-003043
Keywords
health policy; health systems; public health; qualitative study
Categories
Funding
- Wellcome Trust [110084/Z/15/Z.]
Ask authors/readers for more resources
The study reveals the challenges faced by pharmaceutical market regulators in Tanzania, including chronic under-resourcing, information gaps, and enforcement challenges, which limit efforts to achieve the goals of the Global Surveillance and Monitoring System.
In 2012, the WHO launched its Global Surveillance and Monitoring System (GSMS) for substandard and falsified medicines, with the aim of improving the quality of reporting and using the data to inform post-market surveillance and build regulatory capacity. However, from a regulatory governance perspective, its effectiveness depends on the willingness and ability of actors 'on the ground' to identify, report and investigate possible infringements and to enforce penalties. This paper presents findings from 27 interviews with representatives of agencies charged with regulating pharmaceutical markets and 4 interviews with pharmaceutical industry representatives in Tanzania. Their experiences provide important insights into how the theorised mechanism between reporting and a reduction in undesirable behaviours can play out in a low-income context, revealing hidden assumptions about regulator behaviour and motivations. A combination of chronic under-resourcing, information gaps and enforcement challenges conspires to limit the efforts of local regulators to achieve the GSMS goals, shedding new light on the relationship between apparent 'misconduct' and structural constraints.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available